Esophageal Cancer Risk with Barrett Esophagus

In U.S. veterans, the annual risk for development of esophageal adenocarcinoma was 0.32%.

Endoscopic screening and surveillance strategies for Barrett esophagus (BE) have been justified by the concept that recognition and monitoring of a precancerous condition should change clinical outcomes. The estimated annual risk for progression from no dysplasia to esophageal adenocarcinoma (EAC) in patients with BE in the U.S. ranged from 0.23% to 2.4% in early studies from tertiary referral centers. However, in more-recent, large, national cohort studies from the Netherlands, Ireland, and Denmark, annual risks were lower at 0.4%, 0.27% and 0.12%, respectively.

In the current population-based, retrospective cohort study, investigators assessed the risk for EAC in 29,536 patients with BE (97% male; 83% Caucasian; mean age, 62 years) from 12…

Reviewing Author

David A. Johnson, MD

Disclosures

Consultant/Advisory boardMedscape/WebMD; Pfizer; CRH Medical Corporation; Aries

EquityCRH Medical Corporation

Editorial boardsMedscape Gastroenterology

Leadership positions in professional societiesAmerican College of Gastroenterology Research Institute Board of Directors